Plexium Inc. has described compounds acting as probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) degradation inducers reported to be useful for the treatment of cancer.

Researchers at GSK plc and University of Dundee have identified heterocyclic compounds reported to be potentially useful for the treatment of tuberculosis.

Lynk Pharmaceuticals Co. Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has synthesized son of sevenless homolog 1 (SOS1) and GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Transneural Therapeutics Inc. has described 5-HT2A receptor modulators reported to be useful for the treatment of depression, anxiety, substance abuse and dependence, and headache.

280Bio Inc. has divulged compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.

Researchers at Leiden University Medical Center and Universiteit Leiden have synthesized anthracyclins reported to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has disclosed quinazolinone derivatives acting as poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis and autoimmune disease.

Yuhan Corp. has described pyrimidine/pyridine derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.